Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: An open-label study to assess pain control

Current Medical Research and Opinion

Volumn 20, Issue 12, 2004, Pages 1967-1977

  Pavelka, Karel ^a   Le Loet, Xavier ^b   Bjorneboe, Olav ^c   Herrero Beaumont, Gabriel ^d   Richarz, Ute ^e,f  

^a INSTITUTE OF RHEUMATOLOGY   (Czech Republic)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c MARTINA HANSENS HOSPITAL   (Norway)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^e Janssen Cilag ^*  (Switzerland)

^f Janssen Cilag   (Switzerland)

Author keywords

Opioids; Osteoarthritis; Pain control; Rheumatoid arthritis; Transdermal fentanyl

Indexed keywords

ANALGESIC AGENT; CELECOXIB; COCODAMOL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FENTANYL; IMMUNOMODULATING AGENT; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; STEROID; TRAMADOL;

ADULT; AGED; ANALGESIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MENTAL HEALTH; NAUSEA; PRURITUS; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SKIN DISEASE; SOMNOLENCE; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING; WELLBEING;

ADMINISTRATION, CUTANEOUS; AGED; ANALGESICS, OPIOID; ARTHRITIS, RHEUMATOID; FEMALE; FENTANYL; HUMANS; MALE; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PAIN; TREATMENT OUTCOME;

EID: 13144252185     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X14120     Document Type: Article

References (53)

1. Hitchcock LS, Ferrell BR, McCafferty M. The experience of continuous non-cancer pain. J Pain Symptom Manage 1994;9:312-8
2. Holman GH. Chronic nonmalignant pain. Clin Geriatr 1997;5:21-41
3. Arthritis Research Campaign, Factfile - arthritis at a glance. Arthritis Research Campaign, Chesterfield, 2002. Available from: http://www.arc.org.uk/ about_arth/astats.htm [accessed 19 October 2004]
4. Anderson KO, Bradley LA, Turner RA, Agudelo CA, Pisko EJ. Pain behaviour of rheumatoid arthritis patients enrolled in experimental drug trials. Arthritis Care Res 1994;7:64-8
5. Buckelew SP, Parker JC. Coping with arthritis pain: a review of the literature. Arthritis Care Res 1989;2:136-45
6. Creamer P, Hochberg MC. Osteoarthritis. Lancet 1997;350:503-8
7. Pinals RS. Mechanism of joint destruction, pain and disability in osteoarthritis. Drugs 1996;52(Supp 3):14-20
8. Wolheim FA. Current pharmacological treatment of osteroarthritis. Drugs 1996;52(Supp3):27-38
9. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. New Engl J Med 1984;310:563-72
10. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and non-steroidal anti-inflammatory drugs. New Engl J Med 1994;331:1675-9
11. Johnson AG, Nguyen TV, Day RO. Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300
12. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14
13. Garcia Rodriguez LA, Hernander-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570-6
14. McQuay H. Opioids in pain management. Lancet 1999;353:2229-32
15. Jadad A, Carroll D, Glynn C, Moore RA, McQuay HJ. Morphine responsiveness of chronic pain: double-blind randomized cross-over study with patient-controlled analgesia. Lancet 1992;339;1367-71
16. Arkinstall W, Sandler A, Goughnour B, et al. Efficacy of controlled release codeine in chronic non-malignant pain: a randomized, placebo-controlled clinical trial. Pain 1995;62:169-78
17. Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H. Randomized trial of oral morphine for chronic non-cancer pain. Lancet 1996;347:143-7
18. Dellemijn PLI, Vanneste JAL. Randomized double-blind active-placebo- controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet 1997;349:753-8
19. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41
20. Peloso PM, Bellamy N, Bensen W, et al. Double blind randomized placebo control trial of controlled release codeine in the treatment of osteoarthritis of the knee or hip. J Rheumatol 2000;27:764-71
21. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of Osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to non-steroidal anti-inflammatory drugs; a double blind, randomized, multicentre, placebo controlled trial. J Rheumatol 1999;26;862-9
22. Caldwell JR, Rapoport RJ, Davis JC, et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage 2002;23:278-91
23. Gonzales GR, Portenoy RK. Selection of analgesic therapies in rheumatoid arthritis: role of opioid medications. Arthritis Care Res 1993;6:223-8
24. Griessinger N, Sittl R, Jost R, Schaefer M, Likar R. The role of opioid analgesics in rheumatoid disease in the elderly population, Drugs Aging 2003;20:571-83
25. Kalso E, Allan L, Dellemijn PLI, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003;7:381-6
26. Pendleton A, Arden N, Dougados M, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2000;59:936-44
27. American Pain Society. Guideline for the management of pain in osteoarthritis, rheumatoid arthritis, and juvenile chronic arthritis. American Pain Society, Glenview, IL, 2002. Available from: http://www.ampainsoc.org/pub/ arthritis.htm [accessed 19 October 2004]
28. Schug SA, Merry AF, Acland RH. Treatment principles for the use of opioids in pain of nonmalignant origin. Drugs 1991;42:228-39
29. Graziotti PJ, Goucke CR. The use of oral opioids in patients with chronic non-cancer pain. Management strategies. Med J Aust 1997;167:30-4
30. Anon. The use of opioids for the treatment of chronic pain: a consensus statement from the American Academy of Pain Medicine and the American Pain Society. Pain Forum 1997;6:77-9
31. Jeal W, Benfield P. Transdermal fentanyl: a review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997;53:109-38
32. Simpson RK, Edmondson EA, Constant CF, Collier C. Transdermal fentanyl as treatment for chronic low back pain. J Pain Symptom Manage 1997;14:218-24
33. Allen L, Hays H, Jensen NH, et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br Med J 2001;322:1154-8
34. Milligan K, Lanteri-Minet M, Borchert K, et al. Evaluation of long term efficacy and safety of transdermal fentanyl in the treatment of chronic non-cancer pain. J Pain 2001;2:197-204
35. Ringe JD, Faber H, Bock O, et al. Transdermal fentanyl for the treatment of back pain caused by vertebral osteoporosis. Rheumatol Int 2002;22:199-203
36. Theodoridis T, Waap I, Schwalen S, Kramer J. Fentanyl in the treatment of pain caused by arthrosis. Z Orthop 2002;140:217-22
37. Berliner M, Schwalen S, Seidel W, Hantzschel H. Fentanyl-TTS in the treatment of pain caused by rheumatoid arthritis. Akt Rheumatol 2002;27:230-5
38. Arnett FC, Edworthy SM, Bloch DA, et al. The Americam Rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
39. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis, part I: osteoarthritis of the hip. Arthritis Rheum 1995;38:1535-40
40. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis, part II: osteoarthritis of the knee. Arthritis Rheum 1995;38:1541-6
41. Bierma-Zeinstra S, Bohnen A, Ginai A, Prins A, Verhaar J. Validity of the American College of Rheumatology criteria for diagnosing hip osteoarthritis in primary care research. J Rheumatol 1999;26:1129-33
42. Bellamy N, Bradley LA. Workshop on chronic pain, pain control, and patient outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1996;39:357-62
43. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-38
44. Ware JE, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). Med Care 1992;30:473-83
45. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patients outcome in arthritis. Arthritis Rheum 1980;23:137-45
46. Bellamy N, Buchanan WW, Goldsmith CH, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the knee or hip. J Rheumatol 1988;15:1833-40
47. Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Inform J 1991;25:411-24
48. Portenoy RK. Current pharmacotherapy of chronic pain. J Pain Symptom Manage 2000;19:S16-S20
49. Wang SC. Emetic and antiemetic drugs. In: Root WS, Hofmann FG, editors. Physiological pharmacology II. New York: Academic Press; 1965, p. 255-328
50. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained release oral morphine in cancer pain: preference, efficacy and quality of life. J Pain Symptom Manage 1997;13:254-61
51. Allan LA, Kalso E, on behalf of the FEN-INT-26 Study Group. Randomised trial of transdermal fentanyl and sustained release oral morphine in chronic low back pain. Presented at the 4th Congress EFIC, Czech Republic, Prague, 2-6 September 2003
52. Knott L. Treating osteoarthritis in practice - the TOP study. Curr Med Res Opin 2000;16:147-52
53. Portenoy RK. Opioid therapy for nonmalignant pain: a clinician's perspective. J Law Med Ethics 1996;24:296-309